Payment overview · 2025
General Payments
$21.40
1 reported records · 1 companies
Healthcare provider profile · identity verified
Steven Guzman Rodriguez, MD
Allopathic & Osteopathic Physicians|General Practice · MANATI, PR · NPI 1356718068
Verified facts
What the public records show
CMS Open Payments records show Steven Guzman Rodriguez, MD received $21.40 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.40 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $21.40 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 105 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
105 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 350 | 89 |
| Famotidine | Famotidine | 319 | 84 |
| Simvastatin | Simvastatin | 260 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 246 | 83 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 210 | 55 |
| Glimepiride | Glimepiride | 204 | 53 |
| Omeprazole | Omeprazole | 197 | 38 |
| Synthroid | Levothyroxine Sodium | 186 | 53 |
| Metformin Hcl | Metformin Hcl | 185 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 178 | 54 |
| Losartan Potassium | Losartan Potassium | 173 | 62 |
| Baclofen | Baclofen | 164 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 46 |
| Lisinopril | Lisinopril | 162 | 50 |
| Montelukast Sodium | Montelukast Sodium | 146 | 49 |
| Sulindac | Sulindac | 142 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 127 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 23 |
| Farxiga | Dapagliflozin Propanediol | 105 | 22 |
| Ezetimibe | Ezetimibe | 101 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 31 |
| Sucralfate | Sucralfate | 84 | 28 |
| Ramelteon | Ramelteon | 81 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 80 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 77 | 24 |
| Dexamethasone | Dexamethasone | 76 | 52 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 17 |
| Finasteride | Finasteride | 73 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 18 |
| Alendronate Sodium | Alendronate Sodium | 70 | 22 |
| Methylprednisolone | Methylprednisolone | 69 | 43 |
| Clonazepam | Clonazepam | 66 | 15 |
| Carvedilol | Carvedilol | 63 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 59 | 21 |
| Memantine Hcl | Memantine Hcl | 56 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 12 |
| Latanoprost | Latanoprost | 53 | 12 |
| Enalapril Maleate | Enalapril Maleate | 52 | 17 |
| Nabumetone | Nabumetone | 52 | 19 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 52 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 12 |
| Sertraline Hcl | Sertraline Hcl | 48 | 12 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 47 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 11 |
| Metformin Hcl Er | Metformin Hcl | 42 | 12 |
| Mometasone Furoate | Mometasone Furoate | 41 | 17 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 11 |
| Trazodone Hcl | Trazodone Hcl | 38 | 12 |
| Allopurinol | Allopurinol | 37 | suppressed |
| Pentoxifylline | Pentoxifylline | 37 | 11 |
| Prednisone | Prednisone | 37 | 17 |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Irbesartan | Irbesartan | 35 | 15 |
| Tramadol Hcl | Tramadol Hcl | 35 | suppressed |
| Alprazolam | Alprazolam | 33 | suppressed |
| Furosemide | Furosemide | 33 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 13 |
| Spironolactone | Spironolactone | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 31 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Azithromycin | Azithromycin | 29 | 23 |
| Buspirone Hcl | Buspirone Hcl | 29 | 13 |
| Glipizide | Glipizide | 29 | suppressed |
| Humalog | Insulin Lispro | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 20 |
| Calcitriol | Calcitriol | 24 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Jentadueto | Linagliptin/Metformin Hcl | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $21.40 · 1 records | AstraZeneca Pharmaceuticals LP | FARXIGA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error